Why Moderna Stock Popped Today
Shares of Moderna (NASDAQ: MRNA) climbed on Tuesday after the biotechnology company announced the start of a clinical trial for its COVID-19 vaccine in children aged 6 months to 11 years. As of 12:45 p.m. EDT, Moderna's stock price was up more than 8%.
Moderna's vaccine, mRNA-1273, is currently authorized for emergency use in adults aged 18 and older. The drugmaker began testing its safety and effectiveness in adolescents 12 to 17 in December. And on Tuesday, Moderna said it dosed the first participants in a phase 2/3 study of mRNA-1273 in younger children.
Moderna plans to enroll roughly 6,750 participants in the study. Each child will receive two doses of mRNA-1273 given 28 days apart, with the first at one of three dose levels: 25 micrograms, 50 micrograms, or 100 micrograms. The participants will be monitored for one year after their second dose.
Source Fool.com
